October 20th 2025
Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.
Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.
October 19th 2025
Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.
T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.
Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.
ASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC
Although the ORR was similar among patients treated with sacituzumab govitecan vs chemotherapy for TNBC, the DOR was higher with sacituzumab govitecan.
PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer
Gedatolisib enhanced PFS in advanced breast cancer, showcasing significant benefits when combined with fulvestrant and palbociclib.
T-DXd-Based Neoadjuvant Therapy Improves pCR in High-Risk, HER2+ Breast Cancer
T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.
Adjuvant T-DXd Improves Efficacy vs T-DM1 in HER2-Positive Breast Cancer
T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.
Giredestrant Combo Improves Efficacy vs SOC in ER+, HER2- Breast Cancer
Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.
Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer
Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.
Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer
Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.
Analyzing Trials and Treatments in HER2+ Breast Cancer
Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.
Japan’s MHLW Receives sNDA for T-DXd Combo in Frontline HER2+ Breast Cancer
Data from the phase 3 DESTINY-Breast09 trial presented at the 2025 ASCO Annual Meeting formed the basis of the supplemental NDA.
Adjuvant Endocrine/Radiation Therapy May Limit Breast Cancer Recurrence
Oncotype DX 21-gene recurrence scores may help select certain patients who are suitable to omit radiotherapy for early-stage breast cancer.
Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer
Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
The safety profile of dato-DXd was consistent with previous clinical trials assessing the agent in breast cancer.
Trastuzumab Deruxtecan Regimen Accepted for Review in HER2+ Breast Cancer
The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast cancer population.
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
Combination therapy of ETX-636 plus fulvestrant is being administered to patients with HR–positive, HER2-negative breast cancer in a phase 1/2 trial.
Companion Diagnostic Earns FDA Approval for Imlunestrant in Breast Cancer
In the phase 3 EMBER-3 trial, Guardant360 CDx was used to identify patients with ESR1-mutated advanced breast cancer who may benefit from imlunestrant.
Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer
The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.
T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup
Planned interim results from the phase 3 DESTINY-Breast05 trial showed no new safety signals with T-DXd in the trial population.
FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer
Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.
The FDA Grants Priority Review to T-DXd/Pertuzumab in 1L Metastatic Breast Cancer
Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.
3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer
Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.
Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer
Data from the phase 3 evERA trial show a trend toward improved overall survival with giredestrant plus everolimus in this breast cancer population.
ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives
THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.
Trastuzumab Pamirtecan Improves PFS in HER2+ Metastatic Breast Cancer
Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.
Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population
Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.
FDA Accepts New Drug Application for Gedatolisib in PIK3CA Wild-Type Breast Cancer
The rolling submission is supported by data from the PIK3CA wild-type cohort of the phase 3 VIKTORIA-1 trial evaluating gedatolisib in advanced breast cancer.
Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer
Results from the monarchE study showed a statistically significant OS improvement with abemaciclib plus ET for patients with HR+/HER2– early breast cancer.
Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches
Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.
MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer
FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.